Objective To explore the effect of yam polysaccharide for the diabetic mice. Methods Ninty mice were randomly divided into three groups ,yam polysaccharide group(n = 30), glibenclamide group (n = 30) and control group(n = 30). Mice were Intraperitoneal injection of alloxan (200mg/kg) to establish diabetic model. Yam polysaccharide group was administered yam polysaccharide for 12d. Results Yam polysaccharide significantly decreased the blood sugar of the diabetic mice. There were not significantly different in two groups (P ＞ 0.05).Conclusion Yam polysaccharide had obvious role in decreasing blood glucose.

In order to explore the value of p63, smoothmuscle actin (alpha-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining. By using immunohistochemistry, the expression of p63, alpha-SMA and CK5/6 was detected. The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and alpha-SMA. In 19 cases of ductal carcinoma in situ (DCIS) and 7 cases of intraductal papillary carcinoma, alpha-SMA positive cells formed a layer of continuous embroider-shaped structure and the p63 positive cells formed a layer of evenly separated embroider-shaped structure around the ducts. There was no cross-reaction between p63 and interstitial myofibroblasts and vascular smooth muscle cells. In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100%. In 5 cases of atypical ductal hyperplasia, there were few positive cells in the ducts. In 19 cases of CDIS, no tumor cells expressed CK5/6. In 19 cases of invasive ductal carcinoma, almost no CK5/6 was detectable. It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells. CK5/6 is of value in differentiating ductal proliferation of varying degrees, especially in the differentiation between cancerous and non-cancerous changes. Simultaneous detection of p63, CK5/6 and alpha-SMA can help increase the diagnostic accuracy of breast diseases.

Objective To evaluate the efficacy of intravitreal injections of conbercept in choroidal neovascularization (CNV) secondary to pathologic myopia (PM).Methods A retrospective case series of 37 eyes of 37 patients affected with CNV secondary to PM treated by intravitreal injections of Conbercept.All the patients were examined with best-corrected visual acuity (BCVA) of Early Treatment Diabetic Retinopathy Study (ETDRS) chart,central macular thickness (CMT) of optical coherence tomography (OCT) at baseline.The initial average letters of ETDRS BCVA was 49.86±8.87,CMT was (306.38±31.01) μm.All eyes were treated with intravitreal Conbercept 0.05 ml (10 mg/ml).Follow up visits were performed monthly after injection.The mean follow-up time was 16.8 months.Injections were repeated according to the situation of BCVA,CMT,subretinal fluid and CNV leakage in follow-up.All eyes received an average of 4.8 injections.BCVA,CMT and ophthalmoscope examination were assessed monthly.The relationship of BCVA improvement and CMT reduction with the data at baseline and number of treatments were analyzed by Spearman Rho correlation respectively.Results During the 1,3,6 and 12 months after treatment,the mean BCVA were all improved with statistically significant difference (t=17.629,P＜0.01).At 12 months,15 eyes (45.9％) had improvement of 15 letters or more,32 eyes (86.5％) had improvement of 5 letters or more,and 1 eye (2.7％) had decreased more than 5 letters.During the 1,3,6 and 12 months after treatment,the mean CMT were all decreased with statistically significant difference (F=43.726,P＜0.01).At 12 months,the retinal fluid of 34 eyes (91.9％) were absorbed completely;33 eyes (89.2％) had angiographic closure at that time.There was no significant relevance between BCVA improvement and sex,age and course of the disease (P＞0.05),but a significant negative correlation was found between the BCVA improvement and BCVA at baseline,injection times (P＜0.05).There was no significant relevance between CMT reduction and sex,age,course of the disease and injection times (P＞0.05),but a significant positive correlation was found between CMT reduction and CMT at baseline (P＜0.05).There were no systemic or ocular serious side effects during the follow up.Conclusions Intravitreal injections of Conbercept showed BCVA improvement and CMT reduction.It appeared to be effective and safe for choroidal neovascularization secondary to pathologic myopia.Intravitreal Conbercept for CNV secondary to PM showed BCVA improvement,CMT reduction and safety.

Objective To observe the baseline characteristics and visual outcomes after two years follow-up of exudative age-related macular degeneration (AMD) patients treated with ranibizumb. Methods Forty-four eyes of 44 patients with exudative AMD were enrolled into this retrospective study, 19 were men and 25 were women. The mean age was 78 years (range 64–92 years). All patients were underwent best corrected visual acuity (BCVA, Early Treatment of Diabetic Retinopathy Study), fundus color photography, fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT). The mean BCVA was (50.36±14.43) letters, the mean central foveal thickness (CFT) was (291.95± 82.19)μm, and the fluorescence leakage area of choroidal neovascularization (CNV) was (7.61±5.84) mm2. All patients received three initial intravitreous injection of ranibizumb (IVR) and were retreated with monthly IVR when needed. The mean follow up time was 25.6 months (range 24–29 months). On 1, 2, 3, 6, 12, 18 and 24 months after treatment, BCVA and OCT were repeated. On 3, 6, 12, 18 and 24 months after treatment, FFA and ICGA were repeated. The change of BCVA, CFT and fluorescence leakage area of CNV were observed. The association of baseline characteristics and two year visual outcomes were analyzed. Results On 1, 2, 3, 6, 12, 18 and 24 months after treatment, the BCVA were improved significantly (t=?1.89,?3.51,?4.61,?4.04,?5.77,?4.69;P<0.05), the CFT were decreased significantly (t=1.51, 2.30, 3.40, 3.28, 3.54, 3.88, 3.73;P<0.05). On 3, 6, 12, 18 and 24 months after treatment, the fluorescence leakage area of CNV were reduced significantly (t=2.12, 2.90, 3.51, 4.12, 4.06;P<0.05). The lower baseline BCVA, the more improved after treatment. The BCVA improvement degree has a negative relationship with baseline BCVA and fluorescence leakage area of CNV (r=0.505,?0.550;P<0.05), but no correlation with baseline CFT (r=0.210, P>0.05). Conclusion Two year visual outcomes of exudative AMD patients treated with ranibizumb is negative correlated with baseline BCVA and fluorescence leakage area of CNV, but not correlated with baseline CFT.

This paper presents the first description of the morphology of Demodex brevis examined by scanning electron microscopy.The authors found that D.brevis can be distinguished from D.folliculorum by the characteristic features of the following structures: the flat gnatho-soma,the humplike podosoma and the absence of transverse striation on its anterior dorsal Surface,the suprecoxal spines,the hypostome,the oral opening,the pedipalpal claws and the claws on legs,and the ennuli of the terminal part of the opisthosoma.The morphology of the above structures observed are briefly compared with those of D.folliculorum.

Objective To evaluate content validity and construct validity of International Classification of Functioning,Disability and Health(ICF)Core Set for patients with organ transplantation.Methods Patients with kidney,liver,heart,or lung transplantation were assessed with ICF Core Set questionnaire,Functional Independence Measure(FIM)and Barthel Index(BI).Content validity was evaluated with frequency and percentage of patients with a problem for each ICF category,while construct validity was evaluated with Spearman correlation between ICF categories with FIM and BI.Results A consecutive sample of 102 patients completed this study.In body functions,10 categories were reported as a problem by more than 30% of the patients,of which 22 categories correlated significantly with FIM or BI.In body structures,structure areas of skin(s810)were reported as a problem by 30% of the patients,of which 3 categories correlated significantly with FIM or BI.In activities and participation,3 categories were reported as a problem by 30% of the patients,of which 15 categories correlated significantly with FIM and BI.In environmental factors,8 categories were reported as a facilitator by 30% of the patients,of which 8 categories correlated significantly with FIM or BI.Conclusion The content validity and construct validity of ICF Core Set for patients early after organ transplantation were good.

To explore the correlation between the C807T polymorphism of platelet membrane glycoprotein I a (GP I a) gene and aspirin resistance in Chinese people, 200 patients with high-risk of atherosclerosis took aspirin (100 mg/d) for 7 days. Platelet aggregation function was detected using adenosine diphosphate (ADP) and arachidonic acid (AA) before and after the administration of aspirin. Then the subjects were divided into three groups according to the results of platelet aggregation function: an aspirin resistant (AR) group, an aspirin semi-responder (ASR) group and an aspirin-sensitive (AS) group. Platelet GP I a gene 807CT polymorphism was examined by means of polymerase chain reaction-sequence specific primers (PCR-SSP). The results showed that T allelic frequency in AR group and ASR group were higher that of AS group (P<0.005), and the prevalence of genotypes (TT+TC) of these two groups was significantly higher than that in AS group (P<0.05). Platelet GP I a T allele was significantly associated with aspirin resistance as revealed by multiple logistic regression (OR=3.76, 95% CI: 2.87-9.58). The results suggest that inherited platelet GP I a variations may have an important impact on aspirin resistance and the presence of GP I a T allele may be a marker of genetic susceptibility to aspirin resistance.
Aspirin/*administration & dosage ; Atherosclerosis/drug therapy ; Atherosclerosis/genetics ; Drug Resistance/*genetics ; Integrin alpha2/*genetics ; Platelet Aggregation Inhibitors/*administration & dosage ; Polymorphism, Genetic/*genetics

Objective To assess the consistency of diagnostic results using optical coherence tomography angiography (OCTA) and fundus fluorescein angiography (FFA) in the central retinal vein occlusion (CRVO).Methods This is a retrospective case series of 26 eyes of 26 patients with CRVO.There were 10 females (10 eyes) and 16 males (16 eyes).The mean age was (49.19±10.50) years.The mean course of the disease was (27.81± 21.60) days.Simultaneous OCTA and FFA were performed in all patients using 7-standard field of Early Treatment Diabetic Retinopathy Study (ETDRS) to evaluate the microaneurysms,nonperfused areas,optical disc/retinal neovascularization and maeular edema.The consistency was evaluated using weighted Kappa statistic values.Kappa≥0.76,consistency is excellent;0.60≤Kappa＜0.75,consistency is good;0.40≤Kappa＜0.60,consistency is general;Kappa＜0.40,consistency is poor.Results Based on OCTA,microaneurysms were found in 23 eyes,nonperfused areas in 16 eyes,optical disc/retinal neovascularization in 8 eyes and macular edema in 21 eyes.Based on FFA,23 eyes were diagnosed to have microaneurysms,14 eyes have nonperfused area,8 eyes have optical disc/retinal neovascularization,22 eyes have macular edema.The consistency was excellent for microaneurysms and optical disc/retinal neovascularization (Kappa=0.772,0.766;P＜0.01),good for nonperfused areas and macular edema (Kappa =0.703,0.600,P＜ 0v01).Conclusion There is high consistency between OCTA and FFA in the diagnosis of microaneurysms,macular edema,nonperfused areas and optical disc/retinal neovascularization in CRVO patients.

Objective To compare the short-term efficacy of conbercept and ranibizumab for macular edema in central retinal vein occlusion (CRVO)and explore the relationship between the integrity of ellipsoidal zone and visual acuity.Methods Forty-four eyes of 44 patients with macular edema in CRVO were enrolled into this retrospective and comparative study.There were 15 eyes of 15 males,29 eyes of 29 females;age ranged from 49-61 years old,with an average age of (54.65±3.10) years.All patients were examined with best-corrected visual acuity (BCVA),intraocular pressure (IOP),slit lamp,fundus photograph,fundus fluorescein angiography (FFA),optical coherence tomography(OCT).BCVA were examined with interactional visual chart and recorded with logarithm of the minimum angle of resolution acuity.Twenty-three eyes were intravitreal injected with conbercept 0.5 mg (group A) and 21 eyes were intravitreal injected with ranibizumab 0.5 mg (group B).There was no statistical difference of age (t =-1.41),gender (x2 =0.55),the percentage of hypertension patients (x2 =0.27),average BCVA (t =-2.06),IOP (t=-2.52),central macular thickness (CMT) (t=-1.96),number of different integrity of ellipsoidal zone patients (x2 =1.00) and number of different types of macular edema patients (x2 =1.03)among the two groups (P＞0.05).The change in BCV.A.and CMT at 3,6 months between the two groups were compared.The relationship between BCVA at 6 months and BCVA,CMT at baseline were explored.The relationship between three groups of ellipsoidal zone and BCVA at baseline were evaluated.The change of BCVA after treatment between the three groups of ellipsoidal zone were Compared.The number of intravitreal injections between two groups was compared.Results During the 3,6 months after treatment,the mean BCVA were all improved with statistically difference in group A 0=5.13,7.39;P＜0.05) and group B (t=6.60,11.52;P＜0.05).There was no significant difference of BCVA at 3,6 moths between group A and group B (t=-0.99,-0.40;P＞0.05).During the 3,6 months after treatment,the mean CMT were all decreased with statistically difference in group A (t=11.58,i5.96;P＜0.05) and group B (t=18.77,35.16;P＜0.05).There was no significant difference of CMT at 3,6 months between group A and group B (t=-1.52,-1.63;P＞0.05).In both groups,BCVA at 6 months was related to BCVA at baseline (r=0.44,0.62;P＜0.05),but not related to CMT at baseline (r=0.19,0.01;P＞0.05).In the two groups,BCVA at baseline was related to the integrity of ellipsoidal zone (r=0.97,0.70;P＜0.05).There was statistical difference of the number of intravitreal injections in the two groups (t =-6.88,P＜0.05).There was no systemic or ocular serious side effects during the follow up.Conclusions Comparing to ranibizumab,conbercept has the same effective to the treatment of macular edema in CRVO,but the number of intravitreal injections is less.The integrity of ellipsoidal zone is related to BCVA.

Objective To compare the efficacy of photodynamic therapy (PDT) alone or in combined with ranibizumab versus ranibizumab monotherapy (intravitreal injection,IVR) in patients with polypoidal choroidal vasculopathy (PCV).Methods 80 eyes of 72 patients with PCV were enrolled into this retrospective and comparative study according to their therapeutic plan.30 eyes of 28 patients,28 eyes of 30 patients and 22 eyes of 21 patients were divided into PDT group,ranibizumab 0.5 mg group (IVR group) or the combination group,respectively.The patients with PCV were diagnosed according to clinical symptoms,optical coherence tomography (OCT) and fluorescent indocyanine green angiography (ICGA).The baseline best-corrected visual acuity (BCVA) before treatment was more than 0.05,and there was no retinal fibrosis and scar for all patients.There was no statistical difference of age (F=0.187),gender (x2 =0.423),average BCVA (F=1.120) and central retinal thickness (CRT) (F=0.431) among three groups (P＞0.05).They had not received any treatment before.Patients received verteporfin PDT in PDT group,3 consecutive monthly IVRs starting day 1 in IVR group,and 3 IVRs after 3 days,1 month,2 months of PDT starting day 1 in combination group.Re-treatment was considered 3 months later if the follow up shown no changes in fundus photography,OCT and ICGA.The average follow-up time was 19 months.BCVA at baseline and follow-up visit at 1,3,6,12 months was measured,and the proportion of patients with ICGA-assessed complete regression of polyps at month 6 was recorded as primary outcome.The CRT was measured at baseline and 6 months as secondary outcome.Results There were significant difference of BCVA at 1,3,6 and 12 months among three groups(F=5.480,5.249,3.222,4.711;P＜0.05).The average BCVA was significantly better at 1,3,6,12 month than that at baseline(t =-6.632,-4.127,-3.904,-4.494;P＜ 0.05) in combination group,and was significantly better at 3,6,12 months than that at baseline (t=-5.636,-3.039,-3.833;P＜0.05) in IVR group.However there was no significant difference of the average BCVA in PDT group between follow-up at 1,3,6,l 2 months and baseline (t=1.973,0.102,-0.100,-0.761;P＞0.05).The proportion of patients with complete regression of polyps at 6 months was higher in PDT (76.7％) or combination group (68.2％) than IVR group (35.7％) (x2=0.003,0.025;P＜0.05).There was no significant difference of CRT among 3 groups at baseline (P=0.651).The mean CRT decreased in all 3 treatment groups over 6 months (t=5.120,3.635,5.253;P＜0.05),but there was no significant difference of CRT among 3 groups (F=1.293,P＞ 0.05).Conclusions Three therapies could effectively decrease CRT.IVR or IVR combined with PDT are both more effective than PDT therapy to improve vision of PCV patients.PDT or PDT combined with IVR was superior to IVR pnly in achieving complete regression of polyps in 6 months in PCV patients.